Safety and efficacy of sofosbuvir plus ledipasvir for Chinese hepatitis C patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16008158

Enrollment

Unknown

Registered

2016-03-26

Start date

2016-03-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

A:sofosbuvir, ledipasvir and ribavirin

B:sofosbuvir, ledipasvir and ribavirin

C:sofosbuvir, ledipasvir

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. CHC patients; 2. Interferon treatment-experienced or treatment naive; 3. Aged 18-70 years.

Exclusion criteria

Exclusion criteria: 1. Patients infected wiht HBV; 2. Patients infected wiht HIV; 3. Patients infected wiht systematic disorders.

Design outcomes

Primary

Measure	Time frame
HCV RNA;	—

Countries

China

Contacts

Public ContactQing-Lei Zeng

The First Affiliated Hospital of Zhengzhou University

zengqinglei2009@163.com+86 371 67966942

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026